Details of the Drug

General Information of Drug (ID: DMDCM9A)

Drug Name

IMT-002

Synonyms

2799-15-7; D-alpha-Methyl DOPA; D-Methyldopa; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; Methyldopa, D-; (R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 8K91SZC8W9; 3-Hydroxy-alpha-Methyl-D-Tyrosine; L-Methyldopa; (+)-alpha-Methyldopa; UNII-8K91SZC8W9; CAS-555-30-6; D-(3,4-Dihydroxyphenyl)-2-methylalanine; Lopac-M-129; D- alpha -Methyl DOPA; Lopac-M-7277; D-3-(3,4-Dihydroxyphenyl)-2-methylalanine; D-.ALPHA.-METHYLDOPA; SCHEMBL1321546; CHEMBL1452561; METHYLDOPA ANHYDROUS, D-; (+)-.ALPHA.-METHYLDOPA; DTXSID50859484; IMT-002; AKOS030242221; NCGC00015631-01; NCGC00015631-02; NCGC00016510-01; NCGC00016510-02; NCGC00016510-03; NCGC00094724-01; NCGC00094724-02; METHYLDOPA IMPURITY D [EP IMPURITY]; D-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-; EN300-225307; Alanine, 3-(3,4-dihydroxyphenyl)-2-methyl-, D-; J-016939; Q27270669; D-.ALPHA.-METHYL-3-(3,4-DIHYDROXYPHENYL)ALANINE; Z1508927176; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methyl-propanoic acid; (2R)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoicacid

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C10H13NO4
Canonical SMILES: CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)N
InChI: InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m1/s1
InChIKey: CJCSPKMFHVPWAR-SNVBAGLBSA-N

Cross-matching ID

PubChem CID: 721860
TTD ID: DQCJ39

References

1	ClinicalTrials.gov (NCT04625595) A Phase 1b, Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose (MAD) Study to Assess the Steady-State Pharmacokinetics and DQ8 Blocking Efficacy of Orally Administered IMT-002 in Patients With Type 1 Diabetes and HLA-DQ8. U.S.National Institutes of Health.